X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (12) 12
aged (11) 11
female (11) 11
cancer (10) 10
male (10) 10
adult (9) 9
metastasis (9) 9
middle aged (9) 9
oncology (9) 9
chemotherapy (7) 7
tumors (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
cancer therapies (5) 5
cisplatin (5) 5
disease-free survival (5) 5
kaplan-meier estimate (5) 5
medical prognosis (5) 5
prognosis (5) 5
[ sdv.can ] life sciences [q-bio]/cancer (4) 4
life sciences (4) 4
sorafenib (4) 4
surgery (4) 4
survival analysis (4) 4
thyroid cancer (4) 4
young adult (4) 4
aged, 80 and over (3) 3
analysis (3) 3
antineoplastic agents - therapeutic use (3) 3
carcinoma (3) 3
colorectal cancer (3) 3
diagnosis (3) 3
drug dosages (3) 3
fluorouracil (3) 3
hematology, oncology and palliative medicine (3) 3
hospitals (3) 3
management (3) 3
multicenter (3) 3
mutation (3) 3
papillary (3) 3
solid tumors (3) 3
studies (3) 3
treatment outcome (3) 3
abridged index medicus (2) 2
adenocarcinoma - pathology (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
biomarkers (2) 2
biomarkers, tumor - genetics (2) 2
care and treatment (2) 2
cisplatin - administration & dosage (2) 2
clinical trials (2) 2
colorectal neoplasms - pathology (2) 2
combination (2) 2
combined modality therapy (2) 2
disease (2) 2
docetaxel (2) 2
dosage and administration (2) 2
double-blind method (2) 2
doxorubicin (2) 2
doxorubicin - administration & dosage (2) 2
efficacy (2) 2
esophageal neoplasms - drug therapy (2) 2
esophageal neoplasms - pathology (2) 2
fluorouracil - administration & dosage (2) 2
follow-up studies (2) 2
france (2) 2
genetics (2) 2
intention to treat analysis (2) 2
leucovorin (2) 2
leucovorin - administration & dosage (2) 2
medical and health sciences (2) 2
medicin och hälsovetenskap (2) 2
medicine, general & internal (2) 2
melanoma (2) 2
melanoma - pathology (2) 2
mesh : antineoplastic combined chemotherapy protocols (2) 2
mesh : female (2) 2
mesh : humans (2) 2
mesh : male (2) 2
mesh : prognosis (2) 2
molecular targeted therapy (2) 2
organoplatinum compounds - administration & dosage (2) 2
oxaliplatin (2) 2
paclitaxel (2) 2
patients (2) 2
phase-ii trial (2) 2
product development (2) 2
radiation therapy (2) 2
regorafenib (2) 2
research (2) 2
retrospective studies (2) 2
risk factors (2) 2
survival (2) 2
survival rate (2) 2
thyroid neoplasms - drug therapy (2) 2
thyroid neoplasms - mortality (2) 2
thyroid neoplasms - pathology (2) 2
thyroid neoplasms - therapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncology, ISSN 0030-2414, 06/2008, Volume 73, Issue 5-6, pp. I - VI
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 23, pp. 2189 - 2197
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 897 - 905
Summary Background No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to... 
Hematology, Oncology and Palliative Medicine | CRITERIA | MALIGNANT-TUMORS | SOLID TUMORS | ONCOLOGY | PAPILLARY | SORAFENIB | INHIBITOR | CARCINOMA | ZD6474 | Carcinoma | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Young Adult | Lung Neoplasms - secondary | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Female | ErbB Receptors - antagonists & inhibitors | Thyroid Neoplasms - mortality | Double-Blind Method | Kaplan-Meier Estimate | Electrocardiography - drug effects | Heart Conduction System - drug effects | Lymphatic Metastasis | Thyroid Cancer, Papillary | Disease-Free Survival | Adenocarcinoma, Follicular | Thyroid Neoplasms - drug therapy | Carcinoma, Papillary | Piperidines - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Adolescent | Quinazolines - adverse effects | Skin Neoplasms - secondary | Survival Analysis | Thyroid Neoplasms - secondary | Aged | Thyroid Neoplasms - pathology | Tyrosine | Care and treatment | Thyroid cancer | Clinical trials | Product development | Metastasis | Vascular endothelial growth factor | Cancer | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Journal Article
Oncotarget, 09/2015, Volume 6, Issue 28, p. 26388
Journal Article
Targeted Oncology, ISSN 1776-2596, 2/2016, Volume 11, Issue 1, pp. 71 - 82
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 79, Issue 8, pp. 15 - 22
Journal Article
Future Oncology, ISSN 1479-6694, 09/2018, Volume 14, Issue 22, pp. 2239 - 2246
Regorafenib is an orally available multikinase inhibitor, currently approved in metastatic chemorefractory colorectal cancer patients. The results of two large... 
regorafenib adverse events | anti-angiogenic treatment | adherence to oral treatment | late lines of treatment | metastatic colorectal cancer | regorafenib | tyrosine-kinase inhibitor | targeted treatment | MULTICENTER | METABOLITES | MANAGEMENT | KINASE INHIBITORS | SORAFENIB | INDUCED HYPOTHYROIDISM | BAY 73-4506 | STRATEGIES | START LOW | ONCOLOGY | PLUS
Journal Article